StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics total assets

Total assets on the balance sheet at the end of each period.

TG Therapeutics's total assets was $1.64B at Jun 30, 2026. For fiscal 2025 it was $1.06B, up 84.1% from the year before. Over ten years it grew 25.1% a year on average. The highest annual figure on record is $1.06B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.06B+84.1%
FY2024Dec 31, 2024$577.69M+75.3%
FY2023Dec 31, 2023$329.59M+70.3%
FY2022Dec 31, 2022$193.57M-49.0%
FY2021Dec 31, 2021$379.63M-39.3%
FY2020Dec 31, 2020$625.64M+283.8%
FY2019Dec 31, 2019$163.01M+95.0%
FY2018Dec 31, 2018$83.62M-14.1%
FY2017Dec 31, 2017$97.38M+77.8%
FY2016Dec 31, 2016$54.78M-51.7%
FY2015Dec 31, 2015$113.47M+30.8%
FY2014Dec 31, 2014$86.75M+80.3%
FY2013Dec 31, 2013$48.11M+118.0%
FY2012Dec 31, 2012$22.07M+51.8%
FY2011Dec 31, 2011$14.54M-22.0%
FY2010Dec 31, 2010$18.64M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.64B+133.4%
Q1 FY2026Mar 31, 2026$1.53B+132.8%
Q4 FY2025Dec 31, 2025$1.06B+84.1%
Q3 FY2025Sep 30, 2025$1.03B+74.9%
Q2 FY2025Jun 30, 2025$702.61M+75.1%
Q1 FY2025Mar 31, 2025$656.69M+75.9%
Q4 FY2024Dec 31, 2024$577.69M+75.3%
Q3 FY2024Sep 30, 2024$586.01M+77.0%
Q2 FY2024Jun 30, 2024$401.21M+81.7%
Q1 FY2024Mar 31, 2024$373.32M+89.2%
Q4 FY2023Dec 31, 2023$329.59M+70.3%
Q3 FY2023Sep 30, 2023$331.07M+51.9%
Q2 FY2023Jun 30, 2023$220.85M-12.2%
Q1 FY2023Mar 31, 2023$197.36M-34.9%
Q4 FY2022Dec 31, 2022$193.57M-49.0%
Q3 FY2022Sep 30, 2022$217.89M-46.8%
Q2 FY2022Jun 30, 2022$251.67M-47.7%
Q1 FY2022Mar 31, 2022$303.03M-44.8%
Q4 FY2021Dec 31, 2021$379.63M-39.3%
Q3 FY2021Sep 30, 2021$409.69M+49.6%
Q2 FY2021Jun 30, 2021$481.40M+63.4%
Q1 FY2021Mar 31, 2021$548.70M+438.7%
Q4 FY2020Dec 31, 2020$625.64M+283.8%
Q3 FY2020Sep 30, 2020$273.86M+193.4%
Q2 FY2020Jun 30, 2020$294.62M+176.4%
Q1 FY2020Mar 31, 2020$101.85M-13.3%
Q4 FY2019Dec 31, 2019$163.01M+95.0%
Q3 FY2019Sep 30, 2019$93.33M-18.4%
Q2 FY2019Jun 30, 2019$106.59M-24.3%
Q1 FY2019Mar 31, 2019$117.54M-2.9%
Q4 FY2018Dec 31, 2018$83.62M-14.1%
Q3 FY2018Sep 30, 2018$114.37M+12.4%
Q2 FY2018Jun 30, 2018$140.72M+39.0%
Q1 FY2018Mar 31, 2018$120.99M-1.8%
Q4 FY2017Dec 31, 2017$97.38M+77.8%
Q3 FY2017Sep 30, 2017$101.78M+34.5%
Q2 FY2017Jun 30, 2017$101.20M–
Q1 FY2017Mar 31, 2017$123.26M–
Q4 FY2016Dec 31, 2016$54.78M–
Q3 FY2016Sep 30, 2016$75.69M–

More TG Therapeutics figures

See a number that looks wrong?